Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel

MT Newswires12minutes ago

The Top and Bottom Contributors to S&P 500's Q4 EPS Growth

Seeking Alpha19minutes ago

Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175

Futu NewsJan 13 23:33 · Ratings

Intra-Cellular surged nearly 35%! Johnson & Johnson plans to spend $10 billion to acquire the company, marking the largest Biotechnology merger in nearly two years!

This is the largest Trade in the biotechnology Industry in nearly two years, and it is also the first Biomedical merger exceeding 10 billion dollars since 2024, indicating a resurgence in merger and acquisition activities in the Medical Care sector. Goldman Sachs stated that the potential financing capacity of large Biopharmaceutical companies is at least 500 billion dollars, providing significant operational space for R&D investment, merger expansion, and more.

wallstreetcnJan 13 22:42

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT NewswiresJan 13 22:07

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

WSJJan 13 21:39